Halozyme Therapeutics (HALO) said Monday that Johnson & Johnson's (JNJ) Janssen-Cilag International has received a positive opinion in Europe recommending an extension of marketing authorization for a subcutaneous formulation of Rybrevant in treating non-small cell lung cancer.
The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is for Rybrevant in combination with Lazcluze and as a monotherapy, Halozyme said.
The company said subcutaneous Rybrevant is co-formulated with its Enhanze drug delivery technology.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。